Publications

Recent publications


  • Botha, N.L., Cloete, K.J., Šmit, Ž., Isaković, K., Akbari, M., Morad, R., Madiba, I., David, O.M., Santos, L.P., Dube, A. and Pelicon, P., 2024. Ionome mapping and amino acid metabolome profiling of Phaseolus vulgaris L. seeds imbibed with computationally informed phytoengineered copper sulphide nanoparticles. Discover Nano, 19(1), p.8..


  • Subramaniam, S., Joyce, P., Ogunniyi, A.D., Dube, A., Sampson, S.L., Lehr, C.M. and Prestidge, C.A., Minimum Information for Conducting and Reporting In Vitro Intracellular Infection Assays. ACS infectious diseases, 10 (2), 337-349


  • Burns, J., Buck, A.C., D’Souza, S., Dube, A. and Bardien, S., 2023. Nanophytomedicines as Therapeutic Agents for Parkinson’s Disease. ACS Omega, 8, 45, 42045–42061.


  • Myburgh, J., Liebenberg, W., Willers, C., Dube, A. and Gerber, M., 2023. Investigation and Evaluation of the Transdermal Delivery of Ibuprofen in Various Characterized Nano-Drug Delivery Systems. Pharmaceutics, 15(10), p.2413.


  • Botha, N.L., Cloete, K.J., Matinise, N., David, O.M., Dube, A. and Maaza, M., 2023. Synthesis, Characterization, Cytotoxicity, and Antibacterial Studies of Persea americana Mill.(Avocado) Seed Husk Mediated Hydronium Jarosite Nanoparticles. Applied Sciences, 13(15), p.8963.


  • Siwak, A.M., Baker, P.G. and Dube, A., 2023. Biosensors as early warning detection systems for waterborne Cryptosporidium. Water Science & Technology, 88(3), pp.615-630.


  • Louw, E.V., Liebenberg, W., Willers, C., Dube, A., Aucamp, M.E. and Gerber, M., 2023. Comparative study on the topical and transdermal delivery of diclofenac incorporated in nano-emulsions, nano-emulgels, and a colloidal suspension. Drug Delivery and Translational Research, 13(5), pp.1372-1389.


  • Rubaka, C., Gathirwa, J.W., Malebo, H.M., Swai, H., Sibuyi, N.R.S., Hilonga, A., Dube, A., 2023. Chitosan-coated liposomes of Carrisa spinarum extract: synthesis, analysis and anti-pneumococcal potency. Bioinspired, Biomimetic and Nanobiomaterials, 12 (1), 12-23.


  • 2. Mudyiwenyama, L., Khoza, S., Dube, A., 2023 Situation analysis on the regulation of nanomedicines in Southern Africa. Frontiers in Medicine, 10:1098830..


  • Dlozi, P.N., Gladchuk, A., Crutchley, R.D., Keuler, N., Coetzee, R. and Dube, A., 2022. Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes. Biomedicine & Pharmacotherapy, 151, p.113189.


  • D'Souza, S., Du Plessis, S.M., Egieyeh, S., Bekale, R.B., Maphasa, R.E., Irabin, A.F., Sampson, S.L. and Dube, A., 2022. Physicochemical and biological evaluation of curdlan-poly (lactic-co-glycolic acid) nanoparticles as a host-directed therapy against Mycobacterium tuberculosis. Journal of Pharmaceutical Sciences, 111(2), pp.469-478.


  • Madiehe, A.M., Moabelo, K.L., Modise, K., Sibuyi, N.R., Meyer, S., Dube, A., Onani, M.O. and Meyer, M., 2022. Catalytic reduction of 4-nitrophenol and methylene blue by biogenic gold nanoparticles synthesized using Carpobrotus edulis fruit (sour fig) extract. Nanomaterials and Nanotechnology, 12, p.18479804221108254.


  • Khoza, L.J., Kumar, P., Dube, A., Demana, P.H. and Choonara, Y.E., 2022. Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. International Journal of Pharmaceutics, 622, p.121893.


  • Dube, A., Egieyeh, S. and Balogun, M., 2021. A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South Africa. Viruses, 13(10), p.2095.


  • Mhambi, S., Fisher, D., Tchokonte, M.B.T. and Dube, A., 2021. Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. Pharmaceutics, 13(9), p.1479.


  • Ramburrun, P., Pringle, N. A., Dube, A., Adam, R. Z., D’Souza, S., Aucamp, M. (2021). "Recent Advances in the Development of Antimicrobial and Antifouling Biocompatible Materials for Dental Applications". Materials, 14(12), 3167.


  • Toullec, C., Le Bideau, J., Geoffroy, V., Halgand, B., Buchtova, N., Molina-Peña, R., Garcion, E., Avril, S., Sindji, L., Dube, A., Boury, F., Jérôme, C. (2021). "Curdlan–Chitosan Electrospun Fibers as Potential Scaffolds for Bone Regeneration". Polymers. 13, 526.


  • Maphasa, R.E., Meyer, M., Dube, A. (2021). "The Macrophage Response to Mycobacterium tuberculosis and Opportunities for Autophagy Inducing Nanomedicines for Tuberculosis Therapy". Frontiers in Cellular and Infection Microbiology. 10:618414.


  • Dube, A., Semete-Makokotlela, B., Ramalapa, B., Reynolds, J., Boury F. (2021). "Nanomedicines for the treatment of infectious diseases: Formulation, delivery, and commercialization aspects". Green Synthesis in Nanomedicine and Human Health (1st ed.). CRC Press. doi: 10.1201/9781003023197-18.


  • Mansor, M.H., Garcion, E., Ramalapa, B., Buchtova, N., Toullec, C., Aucamp, M., Le Bideau, J., Hindré, F., Dube, A., Alvarez-Lorenzo, C., Galleni, M., Jérôme, C., Boury F. (2021). "Polymer-based protein delivery systems for loco-regional administration". Green Synthesis in Nanomedicine and Human Health (1st ed.). CRC Press. doi: 10.1201/9781003023197-17.


  • Heo, J., Sobiech, T.A., Kutscher, H.L., Chaves, L., Sukumaran, D.K., Karki, S., Dube, A., Prasad, P.N., Reynolds, J.L. (2021). "Hybrid Curdlan Poly (γ‐Glutamic Acid) Nanoassembly for Immune Modulation in Macrophage". Macromolecular Bioscience. 2021, 21, 2000358.


  • Tshweu, L. L., Shemis, M.A., Abdelghany, A., Gouda, A., Pilcher, L.A., Sibuyi, N.R.S., Meyer, M., Dube, A., Balogun, M.O. (2020). "Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin". RSC Advances 10(34): 19770-19780.


  • Lerata, M.S., D’Souza, S., Sibuyi, N.R.S., Dube, A., Meyer, M., Samaai, T., Antunes, E.M., Beukes, D.R. (2020). "Encapsulation of Variabilin in Stearic Acid Solid Lipid Nanoparticles Enhances Its Anticancer Activity in Vitro". Molecules 25(4), 830.


  • Ndumiso, M., Buchtová, N., Husselmann, L., Mohamed, G., Klein, A., Aucamp, M., Canevet, D., D’Souza, S., Maphasa, R.E., Boury, F., Dube, A. (2020). "Comparative whole corona fingerprinting and protein adsorption thermodynamics of PLGA and PCL nanoparticles in human serum." Colloids and Surfaces B: Biointerfaces 188, 110816.


  • Zhou, D.T., Maponga, C.C., Madhombiro, M., Dube, A., Mano, R., Nyamhunga, A., Machingura, I., Manasa, J., Hakim, J.Z., Chirenje, M., Mudzviti, T., Nhachi, C., Ma, Q., Di Francesco, R., Masanganise, R., Morse, G.D. (2019). "Mentored postdoctoral training in Zimbabwe: A report on a successful collaborative effort". Journal of Public Health in Africa 10:1081


  • Samkange, T., D'Souza, S., Obikeze, K., Dube, A. (2019). "Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin." Journal of Pharmacy and Pharmacology 71: 1497-1507.


  • Sousa, C., L. F. Gouveia, B. Kreutzer, B. Silva-Lima, R. E. Maphasa, A. Dube., M. Videira (2019). "Polymeric Micellar Formulation Enhances Antimicrobial and Anticancer Properties of Salinomycin." Pharmaceutical Research 36(6): 83.


  • Sibuyi, N. R. S., Moabelo, K. L., Meyer, M., Onani, M. O., Dube, A., Madiehe, A. M. (2019). "Nanotechnology advances towards development of targeted-treatment for obesity". Journal of Nanobiotechnology, 17(1), 1-21.


  • Omarch, G., Kippie, Y., Mentor, S., Ebrahim, N., Fisher, D., Murilla, G., Swai, H., Dube, A. (2019). "Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes." Artificial Cells, Nanomedicine, and Biotechnology 47(1): 1428-1436.


  • Dube, A. (2019). "Nanomedicines for Infectious Diseases." Pharmaceutical Research 36(4): 63.


  • Bekale, R. B., Du Plessis, S.-M., Hsu, N.-J., Sharma, J.R., Sampson, S.L., Jacobs, M., Meyer, M., Morse, G.D., Dube, A. (2018). "Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines." Pharmaceutical Research 36(1): 8.


  • Tukulula, M., L. Gouveia, P. Paixao, R. Hayeshi, B. Naicker and Dube, A. (2018). "Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages." Pharmaceutical Research 35(6): 111.


  • Manyarara, T. E., S. Khoza, A. Dube., C. C. Maponga. (2018). "Formulation and characterization of a paediatric nanoemulsion dosage form with modified oral drug delivery system for improved dissolution rate of nevirapine." MRS Advances: 1-17.


  • Dube, A. and N. Ebrahim (2017). The nanomedicine landscape of South Africa. Nanotechnology Reviews. 6: 339.


  • Dube, A. and J. L. Reynolds (2016). "Modulation of Innate Immune Responses Using Nanoparticles for Infectious Disease Therapy." Current Bionanotechnology 2(1): 60-65.


  • Tukulula, M., R. Hayeshi, P. Fonteh, D. Meyer, A. Ndamase, M. T. Madziva, V. Khumalo, P. Lubuschagne, B. Naicker, H. Swai., Dube, A. (2015). "Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities." Pharmaceutical Research 32(8): 2713-2726.


  • Melariri, P., L. Kalombo, P. Nkuna, A. Dube, R. Hayeshi, B. Ogutu, L. Gibhard, C. deKock, P. Smith, L. Wiesner., H. Swai (2015). "Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice." International Journal of Nanomedicine 10: 1493-1503.


  • Kutscher, H. L., F. Makita-Chingombe, S. DiTursi, A. Singh, A. Dube, C. C. Maponga, G. D. Morse., J. L. Reynolds. (2015). "Macrophage Targeted Nanoparticles for Antiretroviral (ARV) Delivery." Journal of personalized nanomedicine 1(2): 40-48.


  • Chang, E. H., J. B. Harford, M. A. W. Eaton, P. M. Boisseau, A. Dube, R. Hayeshi, H. Swai., D. S. Lee. (2015). "Nanomedicine: Past, present and future – A global perspective." Biochemical and Biophysical Research Communications 468(3): 511-517.